orbenin-dc- cloxacillin benzathine suspension
merck sharp & dohme corp. - cloxacillin benzathine (unii: ac79l7pv2g) (cloxacillin - unii:o6x5qgc2vb) - cloxacillin 500 mg in 7.5 ml - indications: orbenin-dc is indicated in the treatment and prophylaxis of bovine mastitis in nonlactating cows due to staphylococcus aureus and streptococcus agalactiae . contraindications: because cloxacillin benzathine is relatively insoluble, orbenin-dc's activity will be prolonged. therefore, orbenin-dc should not be used for the occasional cow which may have a dry period of less than 4 weeks. this precaution will avoid residues in the milk following removal of the colostrum.
dry-clox- cloxacillin benzathine gel
boehringer ingelheim animal health usa inc. - cloxacillin benzathine (unii: ac79l7pv2g) (cloxacillin - unii:o6x5qgc2vb) - cloxacillin 500 mg in 10 ml - for the treatment of mastitis in dairy cows during the dry period. dry-clox has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with dry-clox is indicated in any cow known to harbor any of these organisms in the udder at drying off, or which has had repeated attacks of mastitis during the previous lactation, or is affected with mastitis at drying off, if caused by susceptible organisms.
cloxacillin benzathine
elanco australasia pty ltd - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent
cloxacillin benzathine
norbrook laboratories australia pty limited - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent
cloxacillin benzathine
norbrook laboratories australia pty limited - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent
cloxacillin benzathine
avet health limited - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent
cloxacillin benzathine
zoetis australia pty ltd - cloxacillin benzathine - unknown - cloxacillin benzathine antibiotic active 0.0 - active constituent
dicloxacillin sodium capsule
physicians total care, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic
dicloxacillin sodium- dicloxacillin sodium capsule
pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic
dicloxacillin sodium capsule
rebel distributors corp - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin sodium 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic